Department of Anaesthesiology, Far Eastern Memorial Hospital, New Taipei City.
Department of Mechanical Engineering, Yuan Ze University, Taoyuan City.
J Int Med Res. 2022 Aug;50(8):3000605221116760. doi: 10.1177/03000605221116760.
To conduct a meta-analysis to compare different dosing scalars of sugammadex in a morbidly obese population for reversal of neuromuscular blockade (NMB).
PubMed®, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar were searched for relevant randomized controlled trials (RCTs) comparing lower-dose sugammadex using ideal body weight (IBW) or corrected body weight (CBW) as dosing scalars with standard-dose sugammadex based on total body weight (TBW) among morbidly obese people after NMB. Mean difference with SD was used to estimate the results.
The analysis included five RCT with a total of 444 morbidly obese patients. The reversal time was significantly longer in patients receiving sugammadex with dosing scalar based on IBW than in patients receiving sugammadex with dosing scalar based on TBW (mean difference 55.77 s, 95% confidence interval [CI] 32.01, 79.53 s), but it was not significantly different between patients receiving sugammadex with dosing scalars based on CBW versus TBW (mean difference 2.28 s, 95% CI -10.34, 14.89 s).
Compared with standard-dose sugammadex based on TBW, lower-dose sugammadex based on IBW had 56 s longer reversal time whereas lower-dose sugammadex based on CBW had a comparable reversal time.
进行荟萃分析比较病态肥胖人群中不同舒更葡糖钠剂量标度用于逆转神经肌肉阻滞（NMB）。
检索 PubMed®、ClinicalTrials.gov、Cochrane 中央对照试验注册中心（CENTRAL）和 Google Scholar，寻找比较使用理想体重（IBW）或校正体重（CBW）作为剂量标度的低剂量舒更葡糖钠与基于总体重（TBW）的标准剂量舒更葡糖钠用于 NMB 后病态肥胖人群的随机对照试验（RCT）。使用均数差值和标准差来估计结果。
分析纳入了 5 项 RCT，共 444 例病态肥胖患者。接受基于 IBW 的舒更葡糖钠剂量标度的患者的逆转时间明显长于接受基于 TBW 的舒更葡糖钠剂量标度的患者（均数差值 55.77s，95%置信区间[CI] 32.01, 79.53s），但接受基于 CBW 的舒更葡糖钠剂量标度的患者与接受基于 TBW 的舒更葡糖钠剂量标度的患者之间没有显著差异（均数差值 2.28s，95%CI -10.34, 14.89s）。
与基于 TBW 的标准剂量舒更葡糖钠相比，基于 IBW 的低剂量舒更葡糖钠的逆转时间延长了 56s，而基于 CBW 的低剂量舒更葡糖钠的逆转时间相当。
